Executive Summary

"Lower PRICED Drugs Act" is not a comprehensive measure to address all obstacles to generic drug entry, the Generic Pharmaceutical Association says. "While GPhA supports the Stabenow-Lott legislation, Pink Sheet readers should not assume, per your headline, that the bill is a 'GPhA Wish List' that will close every loophole and address all of the generic industry's concerns regarding user fees," the association states in response to the title of a 1chart in a story in "The Pink Sheet" covering the emerging debate on generic user fees (2"The Pink Sheet" Feb. 27, 2006, p. 8). "Although the Stabenow-Lott bill is a very positive measure that addresses many unintended loopholes that delay generics from coming to market, such as abuse of the citizen petition process, there are more loopholes that remain"...